Steven C. Gilman, Director at KERYX BIOPHARMACEUTICALS INC (KERX), sold 1,333 shares at $5.22 ($7K) on 2018-05-29, disclosed to the SEC on 2018-05-31.
Scheduled sale ($7k) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| Filing → |
| VCEL | SELL | 2024-09-20 | $531K | — | Filing → |
| VCEL | SELL | 2024-09-05 | $243K | — | Filing → |
| AKBA | SELL | 2022-06-07 | $2K | — | Filing → |